PL3384292T3 - Test serologiczny do kontrolowania terapii raka HPV16-dodatniego - Google Patents

Test serologiczny do kontrolowania terapii raka HPV16-dodatniego

Info

Publication number
PL3384292T3
PL3384292T3 PL17835602T PL17835602T PL3384292T3 PL 3384292 T3 PL3384292 T3 PL 3384292T3 PL 17835602 T PL17835602 T PL 17835602T PL 17835602 T PL17835602 T PL 17835602T PL 3384292 T3 PL3384292 T3 PL 3384292T3
Authority
PL
Poland
Prior art keywords
therapy
control
positive cancer
serological test
hpv16 positive
Prior art date
Application number
PL17835602T
Other languages
English (en)
Polish (pl)
Inventor
Ralf Hilfrich
Original Assignee
Abviris Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abviris Deutschland Gmbh filed Critical Abviris Deutschland Gmbh
Publication of PL3384292T3 publication Critical patent/PL3384292T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081DNA viruses
    • C07K16/084Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL17835602T 2016-12-13 2017-12-13 Test serologiczny do kontrolowania terapii raka HPV16-dodatniego PL3384292T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102016124171.7A DE102016124171A1 (de) 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen
EP17835602.8A EP3384292B1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma
PCT/EP2017/082506 WO2018108957A1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma

Publications (1)

Publication Number Publication Date
PL3384292T3 true PL3384292T3 (pl) 2021-10-25

Family

ID=61027644

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17835602T PL3384292T3 (pl) 2016-12-13 2017-12-13 Test serologiczny do kontrolowania terapii raka HPV16-dodatniego

Country Status (22)

Country Link
US (2) US10852303B2 (https=)
EP (1) EP3384292B1 (https=)
JP (2) JP7329244B2 (https=)
KR (1) KR102433541B1 (https=)
CN (1) CN110073219B (https=)
BR (1) BR112019011681A2 (https=)
CA (1) CA3045729A1 (https=)
CY (1) CY1124297T1 (https=)
DE (1) DE102016124171A1 (https=)
DK (1) DK3384292T3 (https=)
ES (1) ES2880489T3 (https=)
HR (1) HRP20211080T1 (https=)
HU (1) HUE054969T2 (https=)
LT (1) LT3384292T (https=)
PL (1) PL3384292T3 (https=)
PT (1) PT3384292T (https=)
RS (1) RS62135B1 (https=)
RU (1) RU2757629C2 (https=)
SI (1) SI3384292T1 (https=)
SM (1) SMT202100421T1 (https=)
WO (1) WO2018108957A1 (https=)
ZA (1) ZA201804516B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102022127779A1 (de) 2022-10-20 2024-04-25 Ralf Hilfrich Serologischer Test zum Nachweis von Antikörpern gegen HPV und Testkit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) * 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
US7067258B2 (en) * 2002-04-30 2006-06-27 Merck & Co., Inc. Human papillomavirus multiplexed assay
CN101245099A (zh) * 2007-02-14 2008-08-20 马润林 重组人乳头瘤病毒l1衣壳蛋白的氨基酸序列及其应用
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
DE102010061028A1 (de) * 2010-12-03 2012-06-06 Ralf Hilfrich Schnelltest zum qualitativen und/oder quantitativen Bestimmen von Körperflüssigkeit enthaltenen Antikörpern gegen humane Papillomviren sowie Vorrichtung zum Durchführen des Schnelltests
DE102011053741A1 (de) * 2011-09-19 2013-03-21 Ralf Hilfrich Verfahren zum Überprüfen der Selbstheilung durch das Immunsystem eines mit humanen Papillomviren infizierten Menschen

Also Published As

Publication number Publication date
SI3384292T1 (sl) 2021-08-31
RU2757629C2 (ru) 2021-10-19
EP3384292B1 (en) 2021-04-21
KR102433541B1 (ko) 2022-08-18
LT3384292T (lt) 2021-07-26
KR20190097155A (ko) 2019-08-20
BR112019011681A2 (pt) 2019-10-15
ZA201804516B (en) 2019-04-24
RS62135B1 (sr) 2021-08-31
CY1124297T1 (el) 2022-07-22
RU2019121882A3 (https=) 2021-04-09
RU2019121882A (ru) 2021-01-15
SMT202100421T1 (it) 2021-09-14
JP2020501162A (ja) 2020-01-16
JP7329244B2 (ja) 2023-08-18
US20190113516A1 (en) 2019-04-18
US11506667B2 (en) 2022-11-22
ES2880489T3 (es) 2021-11-24
CN110073219B (zh) 2023-09-05
CN110073219A (zh) 2019-07-30
US20200408768A1 (en) 2020-12-31
EP3384292A1 (en) 2018-10-10
JP2023029377A (ja) 2023-03-03
DK3384292T3 (da) 2021-06-28
WO2018108957A1 (en) 2018-06-21
HRP20211080T1 (hr) 2021-10-01
HUE054969T2 (hu) 2021-10-28
CA3045729A1 (en) 2018-06-21
US10852303B2 (en) 2020-12-01
DE102016124171A1 (de) 2018-06-14
PT3384292T (pt) 2021-07-22

Similar Documents

Publication Publication Date Title
CY2024035I2 (el) Συνθεσεις αντισωματων για τη θεραπεια ογκων
HUE054012T2 (hu) Kombinációs terápia rák ellen
EP3463464A4 (en) ASSOCIATION TREATMENT
HRP20181895T1 (hr) Terapijska hpv16 cjepiva
KR102355950B9 (ko) Tigit에 대한 항체
EP3522966A4 (en) PATIENT INTERFACES
HUE053903T2 (hu) Kombinációs terápia rák ellen
HUE062816T2 (hu) Onkolitikus vakciniavírus
ECSP17015977A (es) Terapia de combinacion
EP3157418C0 (en) DETECTION OF HUMAN-MACHINE INTERACTION ERRORS
PL3423087T3 (pl) Skojarzona terapia przeciwnowotworowa
MA42133A (fr) Modulateurs du ccr2
LT3102123T (lt) Galūnės turniketas
DK3099618T4 (da) Kranstyring
DK3215607T3 (da) Phagterapi
PL3622953T3 (pl) Leczenie skojarzone nowotworu
IL260347A (en) Therapeutic anti-cd9 antibody
EP3413927A4 (en) CANCER THERAPY
HUE046181T2 (hu) Javított ellenanyagok IL-6 ellen
IL249250B (en) Novel combinations for antigen based therapy
BR112016026046A2 (pt) Uso de compostos de tienotriazolodiazepina
DK3172634T3 (da) Reguleringsarmatur
FI20165867A7 (fi) Valoherkiste
PL3563837T3 (pl) Terapia bakteriofagami
DK3408265T3 (da) Terapeutiske forbindelser